430 related articles for article (PubMed ID: 24559687)
21. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.
Torres J; Regan PL; Edo R; Leonhardt P; Jeng EI; Rappaport EF; Ikegaki N; Tang XX
Int J Oncol; 2010 Oct; 37(4):983-91. PubMed ID: 20811720
[TBL] [Abstract][Full Text] [Related]
22. No evidence for the presence of an imprinted neuroblastoma suppressor gene within chromosome sub-band 1p36.3.
Hogarty MD; Winter CL; Liu X; Guo C; White PS; Look AT; Brodeur GM; Maris JM
Cancer Res; 2002 Nov; 62(22):6481-4. PubMed ID: 12438240
[TBL] [Abstract][Full Text] [Related]
23. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
Hu HL; He LJ
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
[TBL] [Abstract][Full Text] [Related]
24. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
Chen Z; Lin Y; Barbieri E; Burlingame S; Hicks J; Ludwig A; Shohet JM
Neoplasia; 2009 Aug; 11(8):753-62. PubMed ID: 19649205
[TBL] [Abstract][Full Text] [Related]
25. High level MycN expression in non-MYCN amplified neuroblastoma is induced by the combination treatment nutlin-3 and doxorubicin and enhances chemosensitivity.
Peirce SK; Findley HW
Oncol Rep; 2009 Dec; 22(6):1443-9. PubMed ID: 19885598
[TBL] [Abstract][Full Text] [Related]
26. MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma.
Lovén J; Zinin N; Wahlström T; Müller I; Brodin P; Fredlund E; Ribacke U; Pivarcsi A; Påhlman S; Henriksson M
Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1553-8. PubMed ID: 20080637
[TBL] [Abstract][Full Text] [Related]
27. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.
Slack A; Chen Z; Tonelli R; Pule M; Hunt L; Pession A; Shohet JM
Proc Natl Acad Sci U S A; 2005 Jan; 102(3):731-6. PubMed ID: 15644444
[TBL] [Abstract][Full Text] [Related]
28. The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage.
Bell E; Premkumar R; Carr J; Lu X; Lovat PE; Kees UR; Lunec J; Tweddle DA
Cell Cycle; 2006 Nov; 5(22):2639-47. PubMed ID: 17172827
[TBL] [Abstract][Full Text] [Related]
29. WP744 is a novel anthracycline with enhanced activity against neuroblastoma.
Inge TH; Harris NL; Wu J; Azizkhan RG; Priebe W
J Surg Res; 2004 Oct; 121(2):187-96. PubMed ID: 15501458
[TBL] [Abstract][Full Text] [Related]
30. CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression.
Liu Z; Yang X; Li Z; McMahon C; Sizer C; Barenboim-Stapleton L; Bliskovsky V; Mock B; Ried T; London WB; Maris J; Khan J; Thiele CJ
Cell Death Differ; 2011 Jul; 18(7):1174-83. PubMed ID: 21252912
[TBL] [Abstract][Full Text] [Related]
31. Dihydropyrimidinase-like protein 3 expression is negatively regulated by MYCN and associated with clinical outcome in neuroblastoma.
Tan F; Wahdan-Alaswad R; Yan S; Thiele CJ; Li Z
Cancer Sci; 2013 Dec; 104(12):1586-92. PubMed ID: 24011394
[TBL] [Abstract][Full Text] [Related]
32. Role of autophagy in chemoresistance: regulation of the ATM-mediated DNA-damage signaling pathway through activation of DNA-PKcs and PARP-1.
Yoon JH; Ahn SG; Lee BH; Jung SH; Oh SH
Biochem Pharmacol; 2012 Mar; 83(6):747-57. PubMed ID: 22226932
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway.
Chen Y; Tsai YH; Tseng SH
Surgery; 2013 Jan; 153(1):4-16. PubMed ID: 22703967
[TBL] [Abstract][Full Text] [Related]
34. Expression and DNA-binding activity of MYCN/Max and Mnt/Max during induced differentiation of human neuroblastoma cells.
Smith AG; Popov N; Imreh M; Axelson H; Henriksson M
J Cell Biochem; 2004 Aug; 92(6):1282-95. PubMed ID: 15258910
[TBL] [Abstract][Full Text] [Related]
35. Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation.
Calao M; Sekyere EO; Cui HJ; Cheung BB; Thomas WD; Keating J; Chen JB; Raif A; Jankowski K; Davies NP; Bekkum MV; Chen B; Tan O; Ellis T; Norris MD; Haber M; Kim ES; Shohet JM; Trahair TN; Liu T; Wainwright BJ; Ding HF; Marshall GM
Oncogene; 2013 Aug; 32(31):3616-26. PubMed ID: 22907436
[TBL] [Abstract][Full Text] [Related]
36. Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells.
Veschi V; Petroni M; Cardinali B; Dominici C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Giannini G
PLoS One; 2012; 7(11):e49139. PubMed ID: 23152863
[TBL] [Abstract][Full Text] [Related]
37. DNA damage-induced regulatory interplay between DAXX, p53, ATM kinase and Wip1 phosphatase.
Brazina J; Svadlenka J; Macurek L; Andera L; Hodny Z; Bartek J; Hanzlikova H
Cell Cycle; 2015; 14(3):375-87. PubMed ID: 25659035
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.
Chesler L; Goldenberg DD; Collins R; Grimmer M; Kim GE; Tihan T; Nguyen K; Yakovenko S; Matthay KK; Weiss WA
Neoplasia; 2008 Nov; 10(11):1268-74. PubMed ID: 18953436
[TBL] [Abstract][Full Text] [Related]
39. p73alpha isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expression in neuroblastoma cells.
Horvilleur E; Bauer M; Goldschneider D; Mergui X; de la Motte A; Bénard J; Douc-Rasy S; Cappellen D
Nucleic Acids Res; 2008 Aug; 36(13):4222-32. PubMed ID: 18583365
[TBL] [Abstract][Full Text] [Related]
40. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE
Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]